492 related articles for article (PubMed ID: 15148491)
1. Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell dose and differentiation.
MacDonald KP; Rowe V; Filippich C; Johnson D; Morris ES; Clouston AD; Ferrara JL; Hill GR
Biol Blood Marrow Transplant; 2004 Jun; 10(6):373-85. PubMed ID: 15148491
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model.
Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L
Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478
[TBL] [Abstract][Full Text] [Related]
3. Long-term engraftment, graft-vs.-host disease, and immunologic reconstitution after experimental transplantation of allogeneic peripheral blood cells from G-CSF-treated donors.
Pan L; Bressler S; Cooke KR; Krenger W; Karandikar M; Ferrara JL
Biol Blood Marrow Transplant; 1996 Oct; 2(3):126-33. PubMed ID: 9199755
[TBL] [Abstract][Full Text] [Related]
4. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.
Hill GR; Morris ES; Fuery M; Hutchins C; Butler J; Grigg A; Roberts A; Bradstock K; Szer J; Kennedy G; Morton J; Durrant S
Biol Blood Marrow Transplant; 2006 Jun; 12(6):603-7. PubMed ID: 16737933
[TBL] [Abstract][Full Text] [Related]
6. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
7. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
[TBL] [Abstract][Full Text] [Related]
8. Donor cell reaction to OKT3 as predictor of chronic graft-vs-host disease in hematopoietic stem cell recipients.
Lindemann M; Ottinger HD; Elmaagacli AH; Trenschel R; Rebmann V; Beelen DW; Grosse-Wilde H
Exp Hematol; 2006 Dec; 34(12):1753-8. PubMed ID: 17157173
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation.
Siegert W; Beyer J; Kingreen D; Blasczyk R; Baurmann H; Schwella N; Schleicher J; Kirsch A; Huhn D
Bone Marrow Transplant; 1998 Sep; 22(6):579-83. PubMed ID: 9758347
[TBL] [Abstract][Full Text] [Related]
10. The role of accessory cells in allogeneic peripheral blood stem cell transplantation.
Tanaka J; Imamura M; Kasai M; Asaka M; Torok-Storb B
Int J Hematol; 1999 Feb; 69(2):70-4. PubMed ID: 10071453
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. Regulatory CD4+CD25hi T cells conserve their function and phenotype after granulocyte colony-stimulating factor treatment in human hematopoietic stem cell transplantation.
Noël G; Bruniquel D; DeGuibert S; Birebent B; Grosset JM; Bernard M; Dauriac C; Lamy-de-la-Chapelle T; Semana G; Brinster C
Hum Immunol; 2008 Jun; 69(6):329-37. PubMed ID: 18571003
[TBL] [Abstract][Full Text] [Related]
13. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.
Zhao XY; Chang YJ; Xu LP; Liu DH; Liu KY; Huang XJ
Bone Marrow Transplant; 2009 Dec; 44(11):721-8. PubMed ID: 19377516
[TBL] [Abstract][Full Text] [Related]
14. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
15. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone.
Devine SM; Brown RA; Mathews V; Trinkaus K; Khoury H; Adkins D; Vij R; Sempek D; Graubert T; Tomasson M; Goodnough LT; DiPersio JF
Bone Marrow Transplant; 2005 Sep; 36(6):531-8. PubMed ID: 16025152
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
[TBL] [Abstract][Full Text] [Related]
17. Superior antileukemic activity of murine peripheral blood progenitor cell (PBPC) grafts mobilized by G-CSF and stem cell factor (SCF) as compared to G-CSF alone.
Hartung G; Uharek L; Zeis M; Glass B; Steinmann J; Dreger P; Krönke M; Schmitz N
Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S16-20. PubMed ID: 9712486
[TBL] [Abstract][Full Text] [Related]
18. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor.
Gyger M; Stuart RK; Perreault C
Bone Marrow Transplant; 2000 Jul; 26(1):1-16. PubMed ID: 10918400
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; García-Latorre E; Moreno-Lafont M; Estrada-García I; Montiel-Cervantes L; Tripp-Villanueva F; Ayala-Sánchez M; García-León LD; Borbolla-Escoboza JR; Mayani H
Ann Hematol; 2006 Feb; 85(2):113-20. PubMed ID: 16311734
[TBL] [Abstract][Full Text] [Related]
20. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
